Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancer

Trial Profile

Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms ESEMPiO; PAINTER
  • Most Recent Events

    • 03 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 29 Sep 2015 Interim results of of 623 patients with updated data up to March 2015 was presented at the European Cancer Congress 2015.
    • 14 Sep 2015 According to an Eisai media release, data from this study will be presented at the 18th Biennial Congress of European Cancer Congress (ECC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top